Guidance on Puberty Blockers for Prescribers & Dispensers
Published: 29/05/25
The Scottish Government has issued an update to prescribers and pharmacists on the use and supply of puberty suppressing hormones.
Following a targeted consultation and advice from the Commission on Human Medicines (CHM), the UK Government laid legislation on 11 December 2024, which came into effect on 01 January 2025, that put in place an indefinite ban on the use of gonadotrophin releasing hormone (GnRH) analogues when prescribed to suppress puberty as part of treating gender incongruence and/or gender dysphoria in children and young people who are under 18 years of age.
The following update gives additional information to pharmacists on the arrangements that apply to medicines that consist of or contain buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin, or triptorelin. This includes, but is not limited to, medicines sold under the brand names: Decapeptyl®, Gonapeptyl Depot®, Salvacyl®, Prostap®, Staladex®, Zoladex®, Synarel®.
Please take the time to read through the information and ensure you are up-to-date with current legislation relating to this topic.
If you have any questions, please contact us at enquiries@cps.scot.
Please note: Due to ongoing discussions with PHS and the Scottish Government, the final round of Adjusted Prices for July 2025 is likely to be agreed and published no later than Tuesday 5th August.